Jason Wittes

Brean Capital assumed coverage of TG Therapeutics Inc (NASDAQ: TGTX) with a Buy rating and $28 target price on promising pipeline. The company has two lead oncology drug candidates in Phase III trials: TG-1101 (a monoclonal antibody that targets aunique epitope on the B-lymphocyte CD20 antigen...

Brean Capital thinks Heron Therapeutics Inc (NASDAQ: HRTX) has a $300 million opportunity over the next five years from yet-to-be-launched Sustol. Sustol is the first and only approved 5-HT3 receptor antagonist with an extended-release effect and 5 days of Chemotherapy Induced Vomiting (CINV)...

Accuray Incorporated (NASDAQ: ARAY) hosted its Analyst Day last week. Brean Capital’s Jason Wittes maintained a Buy rating for the company, with a price target of $12, saying that the meeting was upbeat and focused on the company’s longer-term transformative strategies. Fiscal...

Amid volatility, Stryker Corporation (NYSE: SYK) shares are down 5 percent in the last six months. Brean Capital’s Jason Wittes upgraded the rating for the company from Hold to Buy, while establishing a price target of $115. Wittes believes that the concerns around the company...

Osiris Therapeutics, Inc. (NASDAQ: OSIR) shares are down 19 percent in the last three months, even after hitting a high at $21.13 on September 17. Brean Capital’s Jason Wittes downgraded the rating on the company from Hold to Sell, while establishing a price target of $8. The...

Shares of Osiris Therapeutics, Inc. (NASDAQ: OSIR) have increased by 19.62 percent year-to-date, reaching a high of $22.64 on July 16. Brean Capital’s Jason Wittes has initiated coverage of Osiris Therapeutics with a Hold rating. While mentioning that the stock was fairly valued at...

In a report published Thursday, Brean Capital analyst Jason Wittes downgraded the rating on Zimmer Holdings, Inc. (NYSE: ZMH) from Buy to Hold. The analyst expects uncertainty regarding the company's performance to persist for the next several quarters, which would keep the stock range bound, at...

In a report published Tuesday, Brean Capital analyst Jason Wittes upgraded the rating on Analogic Corporation (NASDAQ: ALOG) from Hold to Buy, and named a $110.00 price target. In the report, Brean Capital noted, "We are upgrading ALOG to a Buy with a $110 target price. This follows a day of...

In a report published Wednesday, Brean Capital analyst Jason Wittes reiterated a Hold rating on Analogic Corporation (NASDAQ: ALOG). In the report, Brean Capital noted, "ALOG reported diluted non-GAAP 2Q15 EPS of $1.08, materially exceeding both our estimate and the consensus estimate of $0.71 and...

In a report written by Brean Capital analyst Jason Wittes, LDR Holding Corp (NASDAQ: LDRH) was initiated with a Buy rating and a $50 one-year price target. Wittes wrote, "Given the degree of differentiation and the potential for LDRH's cervical disc technology to disrupt the current...

In a report published Thursday, Brean Capital analyst Jason Wittes reiterated a Buy rating and $125.00 price target on Teleflex Incorporated (NYSE: TFX). In the report, Brean Capital noted, "We are projecting fourth quarter Adjusted EPS of $1.39 and revenues up 5.7% to $476 million, both of which...

In a report published Thursday, Brean Capital analyst Jason Wittes reiterated a Buy rating and $125.00 price target on Teleflex (NYSE: TFX). In the report, Brean Capital noted, “We recently met with Chairman and CEO Benson Smith, CFO Thomas Powell, Executive Vice President of Americas (previously...

In a report published Friday, Brean Capital analyst Jason Wittes reiterated a Buy rating and $12.00 price target on Accuray (NASDAQ: ARAY). In the report, Brean Capital noted, “We have been getting questions about ARAY's upcoming quarter, given the likelihood like many other companies (and as they...